Source comparison
TB-500 vs Stem Cell Therapy: Mechanism Comparison
Primary Mechanism Actin regulation, cell migration signaling, angiogenesis upregulation Cellular differentiation into tissue-specific cell types (bone, cartilage, muscle) TB-500 enhances existing biology; stem cells replace damaged structures Origin of Therape
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Actin regulation, cell migration signaling, angiogenesis upregulation
- Cellular differentiation into tissue-specific cell types (bone, cartilage, muscle)
- TB-500 enhances existing biology; stem cells replace damaged structures
- Origin of Therapeutic Effect
- Synthetic peptide binds to endogenous proteins in existing cells
- Harvested multipotent cells from bone marrow or adipose tissue
- One is a chemical signal; the other is living cellular material
- FDA Regulatory Status
- Not approved for human therapeutic use; exists as research peptide
- Autologous MSCs under enforcement discretion (21 CFR 1271); allogenic requires BLA
- Neither has full approval for musculoskeletal indications outside investigational protocols
- Administration Complexity
- Subcutaneous or intramuscular self-injection; reconstitution from lyophilized powder required
- Requires sterile harvest (bone marrow aspiration or liposuction), lab processing, and image-guided re-injection
- TB-500 can be self-administered; stem cells require medical procedure and lab isolation
- Typical Dosing Protocol
- 2–5mg twice weekly for 4–6 weeks, then maintenance dosing
- Single injection of 10–100 million cells, sometimes repeated at 3–6 month intervals
- TB-500 is a repeated-dose protocol; stem cells are often one-time or infrequent injections
- Cost Range
- $200–$600 for 6-week protocol (research peptide sourcing)
- $3,000–$15,000 per treatment depending on cell count and facility
- Stem cell therapy is 10–50× more expensive than a TB-500 protocol